.png)
.png)
Latest news from BIA
BIA launches Comprehensive Spending Review priorities to turn UK into a life sciences superpower
The BioIndustry Association (BIA) has today launched its recommendations for the Comprehensive Spending Review, the report ‘Becoming a life sciences superpower’, explains the policies that the Government can implement to turbo charge growth in the innovative UK biotech and life sciences sector.
New report reveals strength of the UK’s thriving genomics sector
The BioIndustry Association (BIA), the Wellcome Sanger Institute and Medicines Discovery Catapult (MDC) have today launched Genomics Nation, showcasing the strength, breadth and opportunity of the UK’s genomics sector for investors, patients and the UK economy.
New investors drawn to UK biotech as global appetite for innovation continues
New analysis shows that biotech shares on the London Stock Exchange continued to out-perform the wider market in the first half of 2021 as international investors were drawn to the UK’s strong science and high-quality companies.
BIA welcomes government’s new Life Sciences Sector Vision
The Life Sciences Sector Vision brings together the collective ambition of the Government and the sector for the UK to be the leading global location for the life sciences businesses to innovate, grow and deliver breakthroughs to patients and the public in all parts of the UK.
Quell Therapeutics Significantly Expands Clinical Manufacturing Capacity for its Engineered Treg Cell Therapies through a Collaboration with the Cell and Gene Therapy Catapult
Collaboration to facilitate an expanded manufacturing footprint to enable clinical supply of Quell’s pipeline, including QEL-001 in liver transplantation and pipeline programs in neuroinflammation and autoimmunity.
Dr John Brown, CBE to retire as Cell and Gene Therapy Catapult’s Chairman
John Brown will retire at the end of 2021 after nine years in the role. Dr John Brown, CBE, FRSE, Chairman of Cell and Gene Therapy Catapult (CGT Catapult), will retire from the role at the end of 2021 after completing three successive terms. The Nomination Committee will establish a process, led by Hilary Newiss, to identify and appoint his successor in due course.
Metrion Biosciences expands into new headquarters to support continued growth
• New 12,000 sq. ft Granta Park, Cambridge (UK) premises more than doubles Metrion’s laboratory space • Custom designed laboratories support new GLP cardiac safety services, expanded cell biology facilities and 384-well automated electrophysiology capability
Coulter Partners secures Chief Executive Officer for Civetta
Cambridge, MA – 21 September 2021 – Coulter Partners, a global Life Sciences, Health and Technology executive search specialist, was delighted to partner with Civetta Therapeutics, LLC, a biotechnology company focused on developing a pipeline of therapies that target beta-propeller proteins, to secure the appointment of Christopher D. Roberts, Ph.D., as Chief Executive Officer.
CEO Update | 20 September 2021
The Prime Minister and the Health Secretary announced the Government’s COVID-19 plan for the Autumn and Winter months. The Government still sees vaccines as the UK’s best defence to avoid any further lockdowns and I was interested to note in the press release that ‘building this defence’ will involve pharmaceutical interventions, which I’m sure will include further work in antibody therapies and antivirals.
Guest Blog | The Talent Vaccine
Dr Jen Vanderhoven, Director of Teesside University’s National Horizons Centre talks about the work being done to establish the UK’s training provision for vaccine manufacturing, advanced therapies and bioprocessing.
BIA blog | Government reshuffle 2021
As many of you will have spotted on the news, Boris Johnson held a major reshuffle last week. While the headlines have mainly focused on the departure of Dominic Raab and Gavin Williamson, there are also some important changes for life sciences.
CEO Update | 13 September 2021
We were kindly hosted by Anthony Browne MP in the Terrace Pavilion of the House of Commons for a lunchtime reception where we launched our report ‘Becoming a life sciences superpower’ which includes our recommendations for the Comprehensive Spending Review (CSR) which has been confirmed by the Chancellor to be on the 27 October.
Please find a selection of featured BIA publications below. To see our full publications library, click here.
Influencing and shaping our sector | BIA update: October 2019 - January 2020
This quarterly update gives an overview of key policy developments and the BIA’s continued engagement with policymakers, regulatory authorities and wider stakeholders on behalf of the UK life sciences sector, from October 2019 to January 2020.
Global and growing - UK biotech financing in 2019
New figures published today (Wednesday 22 January 2020) by the UK BioIndustry Association (BIA) and Informa Pharma Intelligence reveal that the UK biotech sector raised £1.3 billion in 2019.
UK life sciences: Catalysing investment and growth
This updated interim report sets out how the UK life sciences sector is driving investment and growth and makes the case for increased cost-effective public investment in the sector.
BIA biotech manifesto 2019
The United Kingdom (UK) will have a general election on Thursday, 12 December. The UK BioIndustry Association (BIA) has launched a biotech manifesto with its recommendations on how political parties can support the innovative UK life sciences sector.
